every patient, the investigator will determine the PMR 
after evaluating ongoing clinical disease response and 
cytogenetic response. In patients who have responded 
to interferon the PMR will be determined to be: 
1. The evaluation point which immediately precedes 
when patients first become interferon resistant 
according to 11.4, or, progress to advanced 
disease. 
2. The evaluation point which immediately precedes 
when patients first show no significant increase 
in the number of Ph- cells or show an increase in 
the number of Ph+ cells (based on a minimum three 
month interval between cytogenetic analyses) . 
13.4 Criteria for Interferon resistance 
1. Failure to achieve at least partial clinical 
response by 3 months. Failure to achieve a 
complete clinical response by 6 months. 
2. Failure to achieve at least a minor cytogenetic 
remission by 1 year. 
3. Failure to achieve a major cytogenetic remission 
by 2 years. 
Cytoreductive Therapy Including Treatment of Blast Phase 
13.5 Criteria for Achieving a Complete Remiss ion/Return to 
Chronic Phase After Cytoreductive Therapy 
1. Marrow consistent with ongoing hematologic 
recovery post-chemotherapy to chronic phase with 
less than 10% blasts noted in differential. 
2. Peripheral smear consistent with ongoing 
hematologic recovery with < 10% blasts noted in 
differential. 
14.0 Criteria for Removal From Study 
14.1 Patients who initially fulfill the criteria in 4.0 and 
are entered into the study but, at a later date fail to 
meet these same criteria prior to harvest or transplant 
will be removed from study. 
14.2 Post-transplant progressive disease as defined by an 
increase in the WBC count to greater than 40,000/mm 3 in 
chronic phase, or the appearance of features of 
accelerated disease or blastic crisis. Patients would 
[172] 
Recombinant DNA Research, Volume 16 
